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ABSTRAK (MALAY LANGUAGE) 
 
FAKTOR-FAKTOR YANG MEMPENGARUHI KENAIKAN KIRAAN 
PLATELET SELEPAS TRANSFUSI PLATELET PADA PESAKIT 
TROMBOSITOPENIK DI HOSPITAL USM 
 
Banyak kajian telah dijalankan untuk menentukan faktor-faktor yang mungkin menyumbang 
kepada kenaikan platelet pasca transfusi. Bagaimanapun, tiada lagi data yang didokumenkan 
boleh didapati dalam institusi kami dalam bidang pengetahuan ini. Oleh itu, kajian ini telah 
dijalankan untuk menentukan faktor-faktor berkaitan transfusi yang boleh mempengaruhi 
kenaikan platelet selepas transfuse pada pesakit trombositopenik. 
 
Kajian kohort kebelakang ini melibatkan 97 pesakit yang menerima 351 transfusi platelet di 
Hospital Universiti Sains Malaysia dalam tempoh Januari 2013 hingga Disember 2014. Kiraan 
platelet pada pra dan pasca telah diukur dengan menggunakan penganalisa hematologi Sysmex 
XE5000 dan kenaikan kiraan yang diperbetulkan (“CCI”) telah dikira pada 1 jam dan 24 jam 
selepas transfusi. Kenaikan lemah ditakrifkan sebagai “CCI” < 7500 m2/L pada 1 jam dan 
“CCI” < 4500 m2/L pada 24 jam. Faktor-faktor yang dianalisis adalah kanser, demam, DIC, 
pendarahan, splenomegali, jenis platelet pekat (rawak berbanding aferesis), keserasian ABO 
dan usia platelet pekat. Regresi logistik mudah (“SLR”) dan berganda (“MLR”) telah 
digunakan untuk analisis statistik dan nilai p < 0.05 dianggap sebagai bernilai. 
 
Kebanyakan pesakit adalah Melayu (92.8%) dengan umur median 47 tahun. Bilangan pesakit 
lelaki dan perempuan adalah hampir sama. Kebanyakan pesakit adalah O positif (40.2%), 
diikuti oleh B positif (27.8%), A positif (26.8%) dan AB positif (5.2%). Min dan median CCI 
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adalah masing-masing 15,834.54 m2/L dan 10, 350 m2/L. Peratusan pesakit mendapat CCI 
bagus adalah 66.1%.  
 
“SLR” dan “MLR” menunjukkan hanya “DIC”, umur platelet dan keserasian ABO adalah 
faktor-faktor bernilai yang mempengaruhi kenaikan platelet pasca transfusi. DIC mendapat 
masing-masing kemungkinan terlaras 5.31 kali dan 4.41kali bagi “CCI” platelet pasca 
transfusi lemah (nilai-p < 0.001, 95%CI=3.06,9.24), dan kerefraktoran platelet transfusi (nilai-
p < 0.001, 95%CI=2.0,9.7). Selain itu, umur platelet > 3 hari mendapat kemungkinan terlaras 
2.2 kali “CCI” lemah berbanding dengan segar platelet (nilai-p = 0.004, 95% CI = 1.29, 3.75). 
Platelet dengan keserasian ABO mendapat 80% ketidakmungkinan terlaras untuk 
mendapatkan “CCI” lemah pasca transfusi berbanding dengan platelet serupa ABO (nilai-p = 
0.011, 95%CI=0.06,0.65). Faktor-faktor klinikal dan makmal lain tidak bernilai secara 
statistik. 
 
Kesimpulannya, pesakit dengan “DIC” dan menerima platelet pekat berusia ≥4 hari akan 
memerlukan lebih banyak platelet transfusi dalam mencapai kenaikan platelet yang 
dikehendaki berbanding dengan pesakit tanpa “DIC” dan yang menerima transfusi ≤3 hari 
platelet pekat. Di samping itu, pesakit yang menerima platelet pekat serasi ABO mungkin 
memerlukan jumlah yang lebih sedikit transfusi platelet berbanding ABO serupa dalam 
mencapai tahap platelet sasaran. 
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ABSTRACT (ENGLISH LANGUAGE) 
 
FACTORS INFLUENCING PLATELET COUNT INCREMENT AFTER 
PLATELET TRANSFUSION AMONG THROMBOCYTOPENIC PATIENTS 
IN HOSPITAL USM  
 
Many studies had been performed to determine the factors that may contribute to post-
transfusion platelet increment. However, no documented data is available in our institution in 
this area of knowledge yet. Therefore, this study was conducted to determine the transfusion-
related factors that may influence post-transfusion platelet increment in thrombocytopenic 
patients. 
 
This retrospective cohort study involved 97 patients who received 351 of platelet transfusions 
in Hospital Universiti Sains Malaysia within the period of January 2013 till December 2014. 
The pre and post transfusion platelet counts were measured by using Sysmex haematology 
analyzer XE5000 and the corrected count increment (CCI) was calculated at 1 hour and 24 
hours post transfusion. Poor increment was defined as CCI<7500 m2/L at 1 hour and 
CCI<4500 m2/L at 24 hours. The analyzed factors included, underlying malignancy, fever, 
DIC, bleeding, splenomegaly, type of platelet concentrates (random versus apheresis), ABO 
compatibility and age of platelet concentrates. Simple (SLR) and multiple logistic regression 
(MLR) were used for statistical analysis and p-value of < 0.05 considered as significant. 
 
Most patients were Malays (92.8%) with a median age of 47 years old. Male and female 
patients were nearly equal in number. Majority of patients were O positive (40.2%) followed 
by B positive (27.8%), A positive (26.8%) and AB positive (5.2%).  The mean and median of 
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CCI was 15,834.54 m2/L and 10,350m2/L, respectively. The proportion patients with good 
CCI was 66.1%.  
 
SLR and MLR showed that only DIC, platelet age and ABO compatibility were significant 
factors influencing post-transfusion platelet increment. DIC had 5.31 and 4.41 time adjusted 
odds for poor post-transfusion platelet CCI (p-value<0.001, 95%CI=3.06,9.24) and platelet 
refractoriness (p- value <0.001,95%CI=2.0,9.7), respectively. Meanwhile, platelet age of >3 
days had 2.2 time adjusted odds of poor CCI compared to fresh platelet (p-value = 0.004, 95% 
CI=1.29,3.75). ABO compatible platelet transfusion had 80% adjusted odds of unlikelihood 
to get poor post-transfusion CCI compared with ABO identical platelet (p-value=0.011, 
95%CI=0.06,0.65). Other clinical and laboratory factors were not statistically significant.  
 
In conclusion, patients with DIC and who receive day ≥4 platelet concentrates will need more 
platelet transfusions to achieve the desirable platelet increment compared to non DIC patients 
and who receiving day ≤3 platelet concentrates patients, respectively. In addition, patients who 
receive ABO compatible platelet concentrates may need fewer platelet transfusion than ABO 
identical in achieving the similar target platelet level.  
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Introduction 
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1.0 INTRODUCTION 
 
Background of the study 
 
Platelets are one type of blood cells which are mainly involved in circulation hemostasis. 
Platelets are anuclear and there are also known as thrombocytes. They are derived from 
megakaryocytes cytoplasm fragments which are situated in the bone marrow and then these 
end products are released to peripheral circulation (Machlus et al., 2014) . A megakaryocyte 
can give rise to 1000-5000 platelets and normally these newly produced platelets are able to 
survive in circulation up to 10 days (Kaushansky K, 2004). It had been estimated that by 
physiological process, a normal adult will have daily platelet loss of about 7 x 109/L (Hanson 
and Slichter, 1985) but in malignancy and severe infection the losses will increase due to 
higher platelet demand (Schiffer et al., 2001). 
 
Platelet function has been well established for its involvement in stopping any bleeding at the 
site of interrupted endothelium. They clump together at the site of injury and platelet plug is 
then developed at the injured site. Initially, platelets will attach to substances outside the 
interrupted endothelium then adhesion will take place. Then, they change shape, turn on 
receptors and secrete chemical messengers and lastly, they connect to each other through 
receptor bridges in a process which is called as aggregation (Yip et al., 2005). 
 
Platelet concentrates as important tools in treating most cases of thrombocytopenia cannot be 
denied. Most clinicians are very keen to transfuse this type of blood component for most 
thrombocytopenic patient with bleeding condition or high risk patient for bleed. However, the 
dilemma for most clinicians and haematologists is their inability to reach desirable post 
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transfusion platelet count increment even after standard calculations for such transfusions have 
been applied.  
 
Many factors have been suggested to influence the corrected count increment of platelet 
transfusion. A study done by Shamee Shatry et al showed that presence of splenomegaly and 
use of antiplatelets gave significant refractoriness in platelet transfusion (Shastry and 
Chaudhary, 2012). Meanwhile, another study found that patients who received ABO-identical 
platelet transfusions had a better increment compared to those who received ABO-compatible 
platelets but incompatible plasma (Heal et al., 1993). 
 
Even though many factors had been proposed by many studies that may influence those 
increments, specific prediction of increment for each patient for platelet transfusion is quite 
troublesome. Most patients may have multiple factors and each factor has its own weightage 
in post-transfusion platelet increment. A few factors that also need to be considered are fever, 
bleeding, disseminated intravascular coagulation (DIC), age, gender, type of platelet 
concentrates and ABO compatibility. 
 
Since there is no local data available pertaining to this issue, it is hoped that the results of this 
study can be used to evaluate the factors which may contribute to post platelet transfusion 
increment in Hospital Universiti Sains Malaysia (USM) thrombocytopenic patients. The result 
of this study can also be used as a reference data for future use by haematologists and clinicians 
among the criteria to be considered prior to transfusion. 
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2.0  LITERATURE REVIEW 
 
2.1  Platelet concentrates 
 
Platelet concentrates can be prepared from whole blood donation (random platelet) or single 
donor apheresis (apheresis platelet). Platelet concentrates derived from whole blood donation 
are produced by using different sequential centrifugation steps.  Selected whole blood 
donations are centrifuged (hard spin) to separate plasma and red blood cells from the buffy 
coat layer containing leucocytes and platelet. Then, the buffy coats will undergo second 
centrifugation (soft spin) to separate leucocytes and residual red blood cells from the platelets. 
The remaining platelet are suspended in a mixture of additive solution and plasma. Blood 
separating device are needed for production of single donor platelet apheresis (Holbroa et al., 
2013). 
 
By comparison, random platelets show less yield of platelet count per mL compared to 
apheresis platelet concentrates. Pusat Darah Negara (PDN) has stated that 60-70mL of random 
platelets contain >5.5 x 1010 platelets and a 250-300 mL of apheresis platelet concentrate 
contains more than 2 x 1011 platelets. Typically, 5-10 units of random platelets are used for 1 
adult dose of platelet transfusion, meanwhile one-unit apheresis is equal to 5-6 unit of platelet 
random in term of platelet concentration (PDN, 2015). 
 
Each unit of random platelets concentrate should increase the platelet count 5000 to 10,000/L 
in the typical 70-kg human. Pools of 4 to 6 units, will contain roughly 3 x 1011 platelets and 
should give a platelet increment of 20,000 to 60,000/L (Denise M. Harmening, 2005). 
Nevertheless, in this modern preparation process, apheresis platelets, and platelet rich plasma 
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or buffy coat platelet concentrates have similar concentration ≈ 1.5 x 109/mL (Heal and 
Blumberg, 2004). 
 
Most of worldwide blood bank centers have used Standard for Blood Banks and Transfusion 
Services, 26th edition or American Association of Blood Banks 2009 guideline or Guide to the 
preparation, Use and Quality Assurance of Blood Component 16th edition as their reference 
bodies to regulate the quality of platelet component products. Thus, either random or apheresis 
platelet concentrates preparation should follow and maintain its quality standard according to 
the above regulations with minimal platelet content of >2.4 x 1011/ unit and the number of 
residual leucocytes and red blood cells of <1 x 106/unit and 5 x 109/unit, respectively (Holbroa 
et al., 2013). 
 
The prepared platelets can be stored up to 7 days with good viability if good standard operating 
procedures have been applied, such as storage at 200C to 240C in citrate phosphate dextrose 
(CPD) or CDP-adenine solution with agitation motion (Cardigan and Williamson, 2003). 
However, in Malaysia, it has been practiced that platelet storage is up to 5 days as following 
the PDN guidelines which state that the shelf life for any platelet concentrate is 5 days from 
collection date (PDN, 2015). 
 
Since earlier days, it has been accepted that platelet concentrates are grouped according to 
their ABH antigens as A and B blood group antigens have been shown to exist on the platelet 
membrane (Aster, 1965). Furthermore, ABO mismatches were recently found to have some 
adverse effects on platelet transfusion efficacy and even toward their recipients themselves 
(Cid et al., 2013).  
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In our centre, we use Trima Accel and Haemonetic MCS+ 9000 as apheresis devices and both 
are licensed for use. Both types of platelet concentrates have their own  advantages and 
disadvantage as illustrated below based on Holbroa et al (Holbroa et al., 2013) ( Table 2.1). 
 
Table 2.1: Comparison of platelet components produced from whole blood or by apheresis.  
Platelet product Advantages Disadvantages 
Random platelet 1. Avaibility 
2. Platelet dose modification 
3. Avoids product waste 
4. No additional donor risk 
1. Multiple donor exposure 
2. Difficult human leucocyte 
antigens (HLA)/ human 
platelet antigens (HPA) 
matching. 
 
Apheresis platelet 1. Less donor exposure 
2. Automation and 
standardization 
3. HLA/HPA matching 
1. Donor availability 
2. Higher production cost 
3. Limited platelet dose 
4. Donor risk from apheresis 
procedure. 
(Adapted from (Holbroa et al., 2013)) 
 
2.2  Indications of platelet transfusion 
 
In general, platelet transfusion is used for the purpose of preventing or treating bleeding 
condition due to thrombocytopenia caused by non-immunologic causes, immunological 
causes or ablative treatment. Table 2.2 shows some examples of causes of thrombocytopenia 
(Bain, 2015). Most institution set a standard of platelet transfusion as prophylactic transfusion 
at threshold level of ≥ 20 x 109 /L platelets. In addition, platelet transfusions continue to be 
used to treat active bleeding as required, independent of platelet levels based on specific patient 
needs and this action is called therapeutic platelet transfusion. A previous study reported that 
eight-fold increased risk of bleeding with platelet level below 5 x 109/L and  a two-fold 
increased risk with platelet count between 5 to 15 x 109/L compared to previously reported 
figure of  20 to 29 x 109/L  (Webert et al., 2006). 
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Table 2.2: Some causes of thrombocytopenia (excluding conditions that usually causes 
pancytopenia).  
Failure of platelet production 
Congenital (inherited 
or resulting from 
intra-uterine events) 
May-Hegglin anomaly, Sebastian syndrome, Bernard-Soulier 
syndrome, megakaryocytic hypoplasia, reticular agenesis, 
placental insufficiency, hemolytic disease of newborn 
 
Inherited but not 
present at birth 
Fanconi anaemia 
 
 
Acquired Anticancer drugs, thiazide, myelodysplastic syndrome, HHV6 
infection, interferon therapy, paroxysmal nocturnal 
hemoglobinuria, alcohol abuse, anorexia nervosa, autoimmune 
acquired amegakaryocytic thrombocytopenia, graft-versus-host 
disease, hypervitaminosis A, copper deficiency, arsenic poisoning. 
 
Increased platelet consumption, destruction or removal-immune mechanism 
Congenital Alloimmune thrombocytopenia (transplacental transfer of 
maternal auto/alloantibody), maternal drug hypersensitivity 
 
Acquired Autoimmune thrombocytopenic purpura (e.g. systemic lupus 
erythematosus, Evans syndrome), alloimmune (e.g. transfer of 
donor lymphocytes during stem cell transplantation, infusion of 
plasma containing platelet alloantibody), drug-induced immune 
thrombocytopenia (e.g. protamine-heparin thrombocytopenia), 
drug-induced autoimmune thrombocytopenia (e.g. gold salt), 
food-associated immune thrombocytopenia (e.g. tahini, lupines 
termis beans), immune thrombocytopenia associated with 
infection (e.g. HIV, cytomegalovirus, mycoplasma pneumoniae), 
post-transfusion purpura, cocaine abuse 
 
Non-immune mechanisms 
Congenital The Schulman-Upshaw syndrome, hereditary phytosterolaemia, 
Kaposiform haemangioendotheliaoma, intrahepatic infantile 
haemangioma, Type IIB vWF disease. 
 
Acquired DIC, thrombotic microangiopathy, post-transplant hepatic veno-
occlusion disease, viral hemorrhagic fevers, Rickettsial infection, 
certain bacterial and protozoal infection, extracorporeal 
circulation, peripheral blood stem cell apheresis, massive 
transfusion, Kaposi sarcoma, M-CSF, snake bite. 
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“Table 2.2. Continued” 
Redistribution of platelets 
  
Congenital Hypersplenism 
 
Acquired Hypersplenism (including acute sequestration in sickle cell 
disease), hypothermia. 
 
Uncertain or complex mechanisms 
congenital Extreme prematurity, Wiskott-Aldrich syndrome, Grey platelet 
syndrome, Chediak-Higashi anomaly, Jacobsen syndrome, certain 
inborn errors of metabolism, Pearson syndrome 
 
Acquired Phototherapy in the neonate, respiratory distress syndrome, 
neonatal herpes simplex infection, neonatal hyperthyroidism, 
miliary tuberculosis, Grave disease, hypothyroidism, pregnancy-
associated thrombocytopenia, Wilson disease.   
( Adapted from(Bain, 2015)) 
 
European and American guidelines, are recommending the use of a threshold of 10 x 109/L as 
recommendation level for transfusion in patients with acute leukemia and chemotherapy-
induced cytopenia. In addition, in  patients with no fever, the acceptable threshold is even 
lower, up until 5 x 109/L but in presence of fever the trigger level for transfusion is usually 
recommended at 20 x 109/L ,whereas platelet counts > 50 x 109/L is recommended before 
surgery or invasive procedures (lumbar puncture, epidural anaesthesia, gastroscopy, and 
biopsy, insertion of indwelling lines, transbronchial biopsy, liver biopsy, laparotomy or similar 
procedures), massive transfusion, disseminated intravascular coagulation and 
cardiopulmonary bypass (British Committee for Standards in Haematology, 2003). 
 
Meanwhile, platelets should be maintained at 100 x 109/L in surgical procedure at critical site 
(brain or eyes), multiple trauma or central nervous system injury. Lower threshold of 10 x109/L 
for prophylactic transfusion is also recommended for certain conditions such as in 
hematopoietic stem cell transplantation and chronic stable thrombocytopenia (Haematology 
and Force, 2003; Centre, 2007).  
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In our local guidelines for platelet transfusion, we use Pusat Darah Negara guidelines as our 
local reference whereby the transfusion threshold level is based on clinical conditions, as 
summarized in Table 2.3 (PDN, 2007). However, PDN guidelines have not included peadiatric 
patients specifically. Thus, Guidelines for platelet transfusion in pediatric patients created by 
Department of Paediatrics, St Mary’s Hospital, London, United Kingdom (UK) can  be used 
in other centres as a reference (Table 2.4) (New, 2006). 
 
A condition of failed two consecutives platelet transfusions to achieve desirable increment is 
called platelet transfusion refractoriness. Platelet transfusion indications and management for 
patients with platelet transfusion refractoriness are commonly difficult to face. A review by 
Eldad Hod and Joseph Schwartz structured an algorithm for managing platelet transfusion 
refractoriness that required identical ABO group and fresh component with cross-matching 
principal, as displayed in Figure 2.1 (Hod and Schwartz, 2008). 
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Table 2.3: Indication for platelet transfusion.  
Clinical indication Cut-Off values of platelet count 
Hematological malignancies <20 x 109/L is the safe limit unless: fever, 
bleeding, on antibiotics or coagulopathy 
 
Procedures: 
1.Bone marrow aspiration and trephine 
biopsy 
<20 x 109/L providing adequate surface 
pressure is applied 
2.Lumbar puncture, epidural, OGDS 
and biopsy, indwelling lines, 
transbronchial biopsy, liver biopsy, 
laparatomy 
<50 x 109/L 
3. For operation at critical sites: eye and 
brain 
<100 x 109/L 
 
 
Massive transfusions: 
1.Acute bleeding <50 x 109/L 
2.Multiple trauma/ Central nervous 
system (CNS) injury 
<100 x 109/L 
 
DIC: 
1.Acute DIC Frequent estimation of platelet count and 
coagulation screen should be done. Aim to 
maintain platelet count at 50> x 109/L 
2. Chronic DIC/ Absence of bleeding Platelet transfusion should not given 
 
Coronary artery bypass graft/ ruptured abdominal aortic aneurysm: 
Pre-operative assessment of medication 
KIV delay surgery for pre-operative 
transfusion 
Should be reserved for those with post-
operative bleeding and surgical cause has 
been excluded. 
 
Immune thrombocytopenia: 
1.Autoimmune thrombocytopenia Only for life-threatening bleeding from 
Gastrointestinal tract / Genitourinary tract 
/CNS and other conditions with severe 
thrombocytopenia (<10 x 109/L) 
2.Neonatal autoimmune 
thrombocytopenia  
Transfuse compatible platelet ASAP, 
ideally HPA-1a negative, HPA-5b negative. 
Platelet prepared from mother should be 
irradiated and washed.  
3.Post transfusion purpura 
 
 
Platelet transfusion usually ineffective  
 
Platelet transfusion disorders: 
Platelet transfusion only indicated if other measures fail to control the bleeding 
 
Platelet transfusion is contraindicated in: 
Thrombotic thrombocytopenic purpura, Heparin induced thrombocytopenia and Kasabach 
Meritt Syndrome. 
(Adapted from (PDN, 2007)) 
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Table 2.4: Suggested platelet transfusion thresholds for neonates.  
Transfusion of platelet 
 
Platelet threshold 
Consider in all neonates 
 
< 30 x 109/L 
Consider if increased bleeding risk, for example: 
1. < 1000 g and < 1 week of age 
2. clinically unstable (e.g. labile blood pressure) 
3. previous major bleeding (e.g. grade 3–4 intraventricular 
haemorrhage) 
4. current minor bleeding (e.g. petechiae) 
5. coagulopathy 
6. planned surgery or exchange transfusion 
< 50 × 109/L 
(Adapted from (New, 2006)) 
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Figure 2.1: Approach for platelet transfusion refractoriness (Adapted from (Hod and 
Schwartz, 2008)). 
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2.3  Platelet selection for transfusion 
  
2.3.1  ABO compatibility 
 
It is well known, from earliest days that ABO blood groups were not essential consideration 
to elucidate normal response to a platelet transfusion. Hence, single donor and multiple donor 
platelet concentrates were given with no regard to the ABO status. In the recent practice, it is 
evident that ABO incompatibility can affect the adequacy of platelet transfusions, in addition, 
it can also have effects on the recipient wellbeing (Lozano and Cid, 2003). 
 
Before we can understand the meaning of ABO compatibility, ABH group antigens on 
platelets need to be understood. Oligosaccharide structures is the main structure needed as a 
reside platform for glycosyltransferase to act, subsequentially on 2 types of precursor 
oligosaccharide chains called paraglobosides. The H gene encodes a fucosyltransferase that 
attaches fucose via an (1-2) linkage to the terminal galactose of type 2 chains. The secretor 
(Se) gene encodes fucosyltransferase that act similarly on type 1 paragloboside chains. 
Individuals whose cells have no sugars added, other than fucose by the H transferase, are 
denoted blood group type O and express the H antigen. In group A, another glycosyltransferase 
adds an additional N-acetyl-galactosamine to the terminal galactose, whereas in B group 
individuals the B gene encodes a B enzyme that adds another galactose via  (l-2) bond 
(Lozano and Cid, 2003). 
 
 When people who have a certain blood type receive blood from someone with a different 
blood type, it may cause their immune system to react. This is called ABO incompatibility. 
Still, most blood bank centres use serology compatibility test which is mediated by antigen 
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antibody reaction only for packed red cells and not for platelet concentrates. Thus, the selection 
for platelet concentrates for transfusion rely more on ABO identical, best matched available 
recipient and donor platelet concentrate ABO group status (Shehata et al., 2009). Furthermore, 
red blood cells contamination in the product is usually negligible (less than 2 mL) and 
compatibility testing is practically not required, but it is recommended to transfuse the donor 
plasma which is ABO-compatible with the recipient, especially neonatal transfusions (Denise 
M. Harmening, 2005). 
  
On the other hand, guidelines of platelet transfusion by British Journal of Hematology 
recommended that platelet transfusion with identical ABO group is the best choice, because 
ABO non-identical platelet transfusion has been associated with poorer platelet count 
increment. Still, administration of ABO non-identical platelets is acceptable transfusion 
practice, in particular, when identical ABO platelet concentrates are in short supply, or when 
HLA-matched platelets are required and the best match is not ABO compatible (Haematology 
and Force, 2003). 
 
Besides that, in the guidelines it is stated that group O platelets should only be used for group 
A, B and AB patients if they have been tested and labelled as negative for high-titre anti A and 
anti B. This becomes a concerns due to the possibility of hemolysis in transfusion of group O 
platelet concentrates to patients of other ABO groups (Haematology and Force, 2003). This 
statement was supported by a retrospective study which showed the occurrence of hemolysis 
due to ABO minor mismatched platelet transfusion, but the incidence was quite rare (Menis et 
al., 2012). 
 
It has been noted that transfusion of ABO-incompatible platelets may end up with 
intravascular hemolysis and it is not definitively known whether ABO matching of platelet 
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transfusion improves the outcomes. Furthermore, any intention to provide ABO-identical 
platelet can be troublesome due to the fact that most centres have limited inventories (Fung et 
al., 2007) . A review article by Shehata et al had made definitions and descriptions of ABO-
matched transfusions based on many researches (Table 2.5)(Shehata et al., 2009). 
 
Table 2.5: Definition of ABO-matched transfusion.  
ABO matched groups Description 
ABO-identical  platelet transfusion as both the donor and the recipient being the 
same ABO type (e.g. Recipient A positive received platelet 
concentrate from donor A positive). 
ABO-compatible  platelet transfusion when the donor platelets do not carry A or B 
antigen that are incompatible with the recipient’s plasma (e.g. 
Recipient A positive received platelet concentrate from donor O 
positive). 
ABO-incompatible  platelet transfusion when the donor platelets do carry A or B 
antigen that are incompatible with the recipient’s plasma (e.g. 
Recipient A positive received platelet concentrate from donor B 
positive). 
ABO-non-identical platelet transfusion to reflect ABO-compatible and ABO-
incompatible transfusion (e.g. Recipient A positive received 
platelet concentrate from donor B or AB or O positive). 
(Adapted from (Shehata et al., 2009)) 
 
The ABO compatibility can also be classified by its cross-matching component, as shown on 
Table 2.6 base on  a review done by Joan Cid (Cid et al., 2013). 
 
Table 2.6: ABO mismatches classification  
Recipient ABO 
type 
ABO-major mismatched 
(recipient has 
isohemagglutinins against 
ABO antigens on donor 
platelet) 
ABO-minor mismatched 
(donor has isohemagglutinins 
against ABO antigens on 
recipient red blood cell) 
A B, AB B, O 
B A, AB A, O 
AB none A, B, O 
O A, B, AB none 
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*Note that as group AB recipients lack anti-A and –B, a major mismatched platelet transfusion 
cannot occur, and as group O platelet lack A or B antigens, a minor mismatched transfusion 
cannot occur ( Adapted from (Cid et al., 2013)). 
 
There are few strategies that can be used to reduce the risk of hemolysis, some centres wash 
or volume reduce the incompatible plasma from the platelet unit. Washing method is most 
effective removing plasma protein, however there are some drawbacks. It can potentially lead 
to decreased platelet function and platelet aggregation in vitro (Tynngård et al., 2010; 
Veeraputhiran et al., 2011). The other strategy that can be applied, only ABO identical 
platelets or ABO major mismatched platelets would be issued and if this component is low in 
stock then washing/volume reducing minor mismatched platelet might be considered to be use 
next (Shehata et al., 2009).    
 
2.3.2  Rhesus-D (RhD) compatibility 
 
The Rhesus (Rh) blood group system is the second most important blood group system, after 
ABO. Until now, the Rh blood group system consists of 50 defined blood-group antigens, 
among which the five antigens D, C, c, E, and e are the most important. The commonly used 
terms Rh factor, Rh positive and Rh negative refer to the presence or absence of D antigen 
only, respectively (Landsteiner and Wiener, 1941). However, Rhesus antigens are not 
expressed on platelet surface. This makes rhesus compatibility for platelet transfusion not so 
important (Dunstan et al., 1984). 
 
Still, RhD-negative patients are best to be given RhD-negative platelet concentrates 
particularly to women who have not reached the menopause. If transfusion of RhD-positive 
platelets is unavoidable, anti-D should be given except for men or women without childbearing 
potential. The main concern for this selection of platelet concentrates is protection of RhD-
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negative females at the childbearing age from developing alloimmunization by receiving RhD-
positive red cells contaminant in platelet concentrates. If alloimmunization occurred in 
subsequent pregnancy, a hemolytic disease of newborn may complicate the RhD-negative 
mother  (Haematology and Force, 2003).  
 
2.3.3  Irradiated platelet concentrates 
 
Any platelet concentrate which undergo gamma-emitting treatment is called irradiated 
platelets. This irradiated platelet concentrates are functionally maintained up to 5 days shelf 
life from collection date and show no clinical significant changes in platelet transfusion (PDN, 
2015). The radiation given should be a minimum dose of 25Gy to consider it effective against 
donor lymphocytes (Murphy et al., 1992). 
 
All patients who have risk of transfusion-associated graft-versus-host disease are highly 
recommended to be transfused with irradiated platelets only (Haematology and Force, 2003). 
According to PDN guidelines there are few condition that require for irradiated platelet 
transfusion, as summarized in table 2.7(PDN, 2015).  
 
Table 2.7: Indications for irradiated platelets.  
1. In cases where blood is taken from related donors 
2. For allogenic stem cell transplants 
3. Infants under 4 months of age 
4. Intrauterine and exchange transfusions 
5. Immuno-compromised patients due to disease or its treatment ie: Severe Combined 
Immune Deficiency Syndrome(SCIDS), Common Variable Immune 
Deficiency(CVID), Malignancy Transplant recipients (bone marrow and solid 
organ), Hematology/Oncology patients 
(Adapted from (PDN, 2015)) 
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2.3.4  Cytomegalovirus-seronegative platelet concentrates 
 
Cytomegalovirus (CMV) is a common virus that infects people of all ages. In the United States, 
nearly one in three children are already infected with CMV by age 5 years. Over half of adults 
by age 40 have been infected with CMV. Once CMV is in a person's body, it stays there for 
life and can reactivate. A person can also be re-infected with a different strain of the virus 
(CDC, 2016). 
 
In the West, transfusion-transmitted CMV infection may cause significant morbidity and 
mortality in immunocompromised CMV-seronegative patients. This type of platelet 
concentrates is indicated for CMV seronegative pregnant women, intrauterine transfusions and 
CMV-seronegative allogeneic haemotopoietic stem cell transplant recipients; CMV-
seronegative blood is also indicated for patients undergoing solid organ transplants, CMV-
seronegative patients with conditions likely to require allogeneic haemotopoietic stem cell 
transplantation and CMV-seronegative patients with HIV infection (Haematology and Force, 
2003). 
 
In Malaysia however, mass screening for CMV as transfusion transmitted infection (TTI) is 
not beneficial as this virus is endemic in this region. A study based on serology survey in 
Hospital Universiti Kabangsaan Malaysia showed 91.8% of thalassemic patients had antibody 
to CMV (Jamal et al., 1998). Meanwhile, in Kelantan the percentage of seropositivity in blood 
donors of CMV antibodies was even higher, about 97.6% (Ahmed et al., 2006). Despite that, 
CNS involvement (as a parameter of severe CMV infection) is significantly higher in 
developed countries like UK (20%), and United States (20%) compared to Malaysia (10.5%) 
(Balasubramaniam et al., 1994). 
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2.3.5  Leucodepleted/ leucoreduced platelet concentrates 
 
A leucoreduced platelet concentrate is a component that most of its leucocytes had been 
removed, where leucocytes count is less than 1 x 106 (PDN, 2015). In achieving this 
leucoreduction, filtration is usually performed either in the blood bank prior to release of the 
platelets concentrate or at the bedside. The main indications to give a leucoreduced platelet 
concentrates are to prevent febrile non-hemolytic transfusion reactions, to prevent or delay the 
development of HLA antibodies and to reduce the risk of transmitting CMV(PDN, 2007). 
 
2.3.6  Platelet transfusion for neonates 
 
There is some additional specification for neonatal platelet transfusion, such as the 
components should be free of clinically significant irregular blood group antibodies, including 
high titre anti-A and anti-B, negative for CMV and should contain > 40 x 109 ⁄ L platelets. 
Meanwhile, for intrauterine transfusion the platelet concentrates should be hyperconcentrated 
platelet components (> 2000 x 109 ⁄ L) prepared from apheresis platelets with the aim of 
limiting the volume of the transfusion to the fetus, should contain < 0.0025 x 109 ⁄ L leucocytes 
in each preparation, should be used within 24 hr after apheresis collection, negative for CMV, 
gamma irradiated and should contain > 120 x 109 ⁄ L platelets in 60 mL of plasma 
(Haematology and Force, 2003; New, 2006). 
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2.4 Monitoring response to platelet transfusion  
 
Calculation of platelet recovery and corrected count increment  
 
Every platelet transfusion should be monitored as its value can be uses as guide in future 
platelet transfusion therapy. However, there is no evidence that monitoring and action taken 
base on the result of responses to platelet transfusions decreases the incidence of bleeding 
event (Schiffer, 2001; Slichter, 2004) . In general, poor corrected count increment (CCI) 
following at least two fresh ABO compatible concentrates transfusion warrant the clinician to 
search for histocompatible platelet, because sometime patient who receives single platelet 
transfusion with poor increment will have satisfactory increment in second transfusion and if 
clinician use only single transfusion as a marker for refractoriness, this data is surely will miss 
leading (Schiffer, 2001). 
 
In calculating the significant increment value of platelet transfusion, CCI and percentage 
platelet recovery (PPR) have been widely used and internationally accepted. Still, few studies 
showed the CCI equation had better value in comparing response of platelet transfusion among 
patients compared to PPR (Bishop et al., 1992; McCullough et al., 2004). Nevertheless, PPR 
is more superior in reflecting the immediate platelet viability, whereas assessing the platelet 
survival  will depend on late platelet CCI estimated after 18-24 hours (hr) or inter-transfusion 
interval (Schiffer, 2001; Haematology and Force, 2003; Slichter, 2004; Rebulla, 2005; 
Blajchman et al., 2008). Both equations require values of platelet level pre and post transfusion 
with correlation to patient body weight for PPR and body surface area for CCI (Haematology 
and Force, 2003; Brecher, 2005).  
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However, there were some contradicting findings for these equations. Hervig et al found that 
these formulas gave some inaccurate results due to bias and unstandardization in automated 
analyzers, while Davis et al illustrated both formulas may not give accurate results in obese 
patient (Davis et al., 1999; Hervig et al., 2004). 
 
A successful platelet transfusion will  be considered in stable patients if the PPR  achieves 
about 67%, but generally accepts minimum of PPR and CCI to be concluded as successful 
transfusion are PPR > 30% at 1 hr post transfusion and >20% at 20-24hr , or a CCI of > 7.5 x 
109/L at 1 hr and >4.5 x 109/L at 20-24hr, respectively (British Committee for Standards in 
Haematology, 2003). 
 
The CCI (X 109/L) is calculated from the corrected count increment (PI), the body surface area 
of the patient in square metres (BSA) and  the dose of platelet transfused ( X 1011( (PD) [in 
general, 1 RDP= 0.6 x 1011 ; 1 apharesis platelet > 2.0 x 1011] (Apelseth et al., 2011) 
 
CCI = PI X BSA X PD-1 
 
While the percentage platelet recovery (PPR) or post-transfusion platelet recovery is 
calculated from the platelet increment (109/L) (PI), the blood volume (BV) in litres and the 
platelet dose transfused (X 109) (PD). The blood volume estimate most commonly used in the 
calculation is 75 mL/Kg (McFarland, 2008). 
 
PPR (%) = PI X BV X PD-1 x 100 
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The actual definition of platelet refractoriness varies, but one widely accepted definition (as 
applied in the Trial to Reduce Alloimmunization to Platelets) is two of 1 hr CCI values on 
consecutive days of less than 5000. Other definition for platelet refractoriness is a consecutive 
CCI less than 7500/L measured 10–60 minutes after a transfusion, and less than 4500/L 
measured 18–24 hr after a transfusion (Hendrickson and Roback, 2009). 
 
2.5  Factors influencing post-transfusion platelet increment 
 
2.5.1  Platelet transfusion factors 
 
2.5.1(a)  ABO compatibility platelet transfusion 
 
There was two trial studies that showed 39 % and 61 % of ABO identical platelet transfusion 
had reduced the frequency of platelet refractoriness in patients with various hematologic 
malignancies, respectively (Carr et al., 1990; Heal et al., 1993). ABO-identical platelet 
transfusion was also associated with significant 27% higher of CCI compared to non-identical 
platelet. Furthermore, this study also concluded that ABO-identical platelet transfusions were 
associated with higher CCI than ABO compatible or ABO incompatible (7500 vs 4800 vs 
3000/L, respectively) ( p-value< 0.05) (Heal et al., 1993).  
 
Besides that, among the patients receiving ABO identical platelets, only 18% became 
refractory to platelet transfusion during their first ten transfusion compared with 53% of the 
non-identical group ( p-value<0.01) and the onset of refractoriness was delayed in recipients 
of ABO identical platelet (Heal et al., 1993). 
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A study by Garratty demonstrated that hemolytic transfusion reaction in major mismatched 
platelet transfusion was not significant. The reason given was that, dilution effect of recipient 
plasma on donor antibodies or the antibodies were neutralized by endothelial based A and B 
antigens may be the possible causes. However, this study could not conclude that major 
mismatches may not influence the post- transfusion platelet increment (Garratty, 1998). 
 
Nonetheless, it has been known for many years that, major mismatched platelet transfusion 
has poor post-transfusion platelet increment and usually has positive correlation with high risk 
bleeding outcome. Few small retrospective studies on hematology-oncology patients have 
reported significantly lower post-transfusion platelet increment after ABO major mismatched 
platelet transfusion compared to ABO matched and ABO minor mismatched platelet groups 
(Heal et al., 1987; Slichter et al., 2005).  
 
2.5.1(b)  Rhesus-D (RhD) status with post-transfusion platelet increment 
 
The general term of RhD positive and negative refer to the presence or absence of the D 
antigen. For platelets however, their surface membrane do not express the Rhesus, Duffy, 
Kidd, Kell and Lutheran antigens. Thus, indirectly makes RhD compatibility insignificant for 
platelet transfusion. A study by Dunstan et al showed the insignificant association of RhD 
status of the patient or donor pertaining to post-transfusion platelet increment (Dunstan et al., 
1984). Yet, it had been regulated that every platelet concentrate need to be labelled with the 
RhD status as its can cause anti-D alloimmunization in RhD negative patients if those patients 
receive RhD positive platelet components (Haematology and Force, 2003) 
 
